App-Based Tracking of Self-Reported COVID-19 Symptoms: Analysis of Questionnaire Data

Martin Zens1, MD, PhD; Arne Brammertz2, Dipl-Vw; Juliane Herpich1, MD; Norbert Südkamp3*, MD, PhD; Martin Hinterseer1*, MD

1Department of Medicine, Kliniken Ostallgäue-Kaufbeuren, Fuessen, Germany
2DESIGN-IT GmbH, Frankfurt, Germany
3University Medical Center Freiburg, Freiburg, Germany
*these authors contributed equally

Corresponding Author:
Martin Zens, MD, PhD
Department of Medicine
Kliniken Ostallgäue-Kaufbeuren
Stadtbleiche 1
Fuessen, 87629
Germany
Phone: 49 8362 500 726
Email: martin.zens@me.com

Abstract

Background: COVID-19 is an infectious disease characterized by various clinical presentations. Knowledge of possible symptoms and their distribution allows for the early identification of infected patients.

Objective: To determine the distribution pattern of COVID-19 symptoms as well as possible unreported symptoms, we created an app-based self-reporting tool.

Methods: The COVID-19 Symptom Tracker is an app-based daily self-reporting tool. Between April 8 and May 15, 2020, a total of 22,327 individuals installed this app on their mobile device. An initial questionnaire asked for demographic information (age, gender, postal code) and past medical history comprising relevant chronic diseases. The participants were reminded daily to report whether they were experiencing any symptoms and if they had been tested for SARS-CoV-2 infection. Participants who sought health care services were asked additional questions regarding diagnostics and treatment. Participation was open to all adults (≥18 years). The study was completely anonymous.

Results: In total, 11,829 (52.98%) participants completed the symptom questionnaire at least once. Of these, 291 (2.46%) participants stated that they had undergone an RT-PCR (reverse transcription-polymerase chain reaction) test for SARS-CoV-2; 65 (0.55%) reported a positive test result and 226 (1.91%) a negative one. The mean number of reported symptoms among untested participants was 0.81 (SD 1.85). Participants with a positive test result had, on average, 5.63 symptoms (SD 2.82). The most significant risk factors were diabetes (odds ratio [OR] 8.95, 95% CI 3.30-22.37) and chronic heart disease (OR 2.85, 95% CI 1.43-5.69). We identified chills, fever, loss of smell, nausea and vomiting, and shortness of breath as the top five strongest predictors for a COVID-19 infection. The odds ratio for loss of smell was 3.13 (95% CI 1.76-5.58). Nausea and vomiting (OR 2.84, 95% CI 1.61-5.00) had been reported as an uncommon symptom previously; however, our data suggest a significant predictive value.

Conclusions: Self-reported symptom tracking helps to identify novel symptoms of COVID-19 and to estimate the predictive value of certain symptoms. This aids in the development of reliable screening tools. Clinical screening with a high pretest probability allows for the rapid identification of infections and the cost-effective use of testing resources. Based on our results, we suggest that loss of smell and taste be considered cardinal symptoms; we also stress that diabetes is a risk factor for a highly symptomatic course of COVID-19 infection.

(J Med Internet Res 2020;22(9):e21956) doi: 10.2196/21956

KEYWORDS
COVID-19; self-reporting; symptom; tracking; app; surveillance; distribution; digital tool; screening
Introduction

COVID-19 was initially characterized as an acute respiratory infection with significant virulence and mortality. Following reports of the first cases in Wuhan, China, in December 2019, the virus spread globally with 9,738,374 confirmed cases as of June 26, 2020 [1]. Previous research has revealed that COVID-19, which is caused by the novel coronavirus SARS-CoV-2, is a systemic disease rather than an isolated acute respiratory illness [2,3]. The diversity in symptoms is the result of SARS-CoV-2 attacking various organs.

The aim of this study was to identify further symptoms and to investigate whether certain symptoms may be used as for screening to differentiate COVID-19 infection from other diseases. A powerful and reliable clinical screening tool may help to identify and isolate SARS-CoV-2–infected individuals and slow down disease prevalence.

Methods

Study Setting and Participants

The COVID-19 Symptom Tracker was developed by DESIGN-IT GmbH, in collaboration with the University Medical Center Freiburg and Kliniken Ostallgaeu-Kaufbeuren, Fuessen Hospital (Figure 1). The first version was released for Apple iOS on April 8, 2020, and for Google Android on April 20, 2020. Within 5 weeks, the app was downloaded 22,327 times. The app was released in German, English, French, and Spanish and advertised through public media (TV, radio, newspaper, online), following a nationwide press release. An initial questionnaire asked for demographic information (age, gender, postal code) and past medical history with relevant chronic diseases. The participants are notified daily by push notifications to report whether they were experiencing symptoms and if they had been tested for SARS-CoV-2. In addition to a binary response regarding the prevalence of symptoms, for some items (eg, fever, cough) we collected additional details like temperature range or expectoration. If users sought professional health care advice (eg, visited a hospital, a private practice, etc), additional questions regarding diagnostics and treatment were asked. Participation was open to all adults (≥18 years). The study was anonymous; a formal consent for participation was not required due to this fact but was asked for regardless.

Figure 1. The COVID-19 Symptom Tracker.

Statistical Analysis

Data were downloaded from the database server. Only data sets of individuals who live in Germany and had completed the entire symptom questionnaire at least once were included in further analysis. Participants were presented as counts, age as mean and standard deviation derived from an age span, and questionnaire items as counts and percentages. For each risk factor and symptom, odds ratios were calculated using binary
logistic regression. Data from untested participants were not included in this analysis.

**Ethics**

Approval of the study design was obtained by the Ethics Committee at the University Medical Center Freiburg (EK 337/20). The committee was very supportive of the project.

**Data and Code Availability**

The anonymous data collected by the COVID-19 Symptom Tracker app can be shared with researchers upon request with a research protocol or due to a question of public interest, if permitted by the ethics committee. The app code is also available upon request. Requests can be sent to the corresponding author. The Laravel PHP script for SQL data extraction is publicly available [4].

**Results**

Between April 8 and May 15, 2020, 22,327 individuals installed the COVID-19 Symptom Tracker on their mobile device. In total, 11,829 (52.98%) participants completed the symptom questionnaire at least once. Of these, 291 (2.46%) stated that they had undergone an RT-PCR (reverse transcription-polymerase chain reaction) test for SARS-CoV-2; 65 (0.55%) reported a positive test result and 226 (1.91%) a negative one. The mean number of reported symptoms in the group of untested participants was 0.81 (SD 1.85). On average, individuals with a negative result reported 4.26 symptoms (SD 2.52) and those with a positive result reported 5.63 symptoms (SD 2.82). All participants were asked to fill out an initial questionnaire on intrinsic risk and demographic data. The self-reported prevalence of risk factors (eg, diabetes: 917/11,538, 7.95%; hypertension: 3268/11,538, 25.19%; and smoking: 3679/11,538, 31.89%) showed a significant correlation with the data provided regularly by the German Federal Office of Statistics [5] and the Ministry of Health [6] (eg, diabetes: 7.2%; hypertension: 24.6%), which suggests that the study cohort is representative of the German population (age group: 18-65 years). Elderly individuals are underrepresented due to the methodology used in this study.

The daily symptom questionnaire requested information on known or suggested symptoms as of April 1, 2020 [7-10] and permitted users to enter additional symptoms as free text. Odds ratios (OR) were calculated for all risk factors and reported symptoms. According to our data, the most significant risk factors are diabetes (OR 8.95, 95% CI 3.30-22.37) and chronic heart disease (OR 2.85, 95% CI 1.43-5.69) (Figure 2). We identified chills, fever, loss of smell, nausea and vomiting, and shortness of breath as the top five strongest predictors for a COVID-19 infection (Figure 2). The OR for loss of smell was 3.13 (95% CI 1.76-5.58); of comparable significance were chills (OR 4.48, 95% CI 2.51-8.01) and fever (OR 4.37, 95% CI 2.44-7.81). Chills, fever, and shortness of breath have been identified and communicated as common symptoms in the mainstream media. Nausea and vomiting (OR 2.84, 95% CI 1.61-5.00) has been reported as an uncommon symptom; however, our data suggest a significant predictive value. The characteristics of the entire cohort are displayed in Table 1.

**Figure 2.** (a) Association between reported symptoms and the odds ratio for a positive SARS-CoV-2 test result; (b) association between reported risk factors and the odds ratio for a positive SARS-CoV-2 test result. Both analyses were carried out in a population of 291 participants who tested via reverse transcription-polymerase chain reaction. Error bars represent 95% CI.
Table 1. Characteristics of participants (N=11,829).

| Characteristic                  | Tested for SARS-CoV-2 | Not tested for SARS-CoV-2 |
|--------------------------------|-----------------------|---------------------------|
|                                | Positive test result  | Negative test result      |
| Participants, n (%))           | 65 (0.55)             | 226 (1.91)                | 11,538 (97.54) |
| Female, n (%)                  | 33 (50.77)            | 109 (48.23)               | 4360 (37.79)  |
| Age (years), mean (SD)         | 42.65 (13.33)         | 41.04 (12.88)             | 44.47 (15.41) |
| Smoker, n (%)                  | 33 (50.77)            | 74 (32.74)                | 3679 (31.89)  |
| Influenza vaccine, n (%)       | 21 (32.31)            | 69 (30.53)                | 3268 (28.32)  |

**Comorbidities, n (%):**

- Diabetes: 14 (21.54) / 7 (3.10) / 917 (7.95)
- Arterial hypertension: 26 (40.00) / 54 (23.89) / 2906 (25.19)
- Chronic lung disease: 22 (33.85) / 51 (22.57) / 1352 (11.72)
- Chronic heart disease: 17 (26.15) / 25 (11.06) / 1020 (8.84)

**Symptoms, n (%):**

- Loss of smell: 31 (47.69) / 51 (22.57) / 325 (2.82)
- Fatigue: 60 (92.31) / 189 (83.63) / 1560 (13.52)
- Shortness of breath: 40 (61.54) / 84 (37.17) / 554 (4.80)
- Fever: 36 (55.38) / 50 (22.12) / 296 (2.57)
- Persistent cough: 55 (84.62) / 164 (72.57) / 1290 (11.18)
- Diarrhea: 34 (52.31) / 92 (40.71) / 670 (5.81)
- Chills: 38 (58.46) / 54 (23.89) / 393 (3.41)
- Headache: 50 (76.92) / 162 (71.68) / 1388 (12.03)
- Sniffling and snorting: 43 (66.15) / 129 (57.08) / 1339 (11.61)
- Nausea and vomiting: 34 (52.31) / 63 (27.88) / 428 (3.71)
- Body aches: 45 (69.23) / 112 (49.56) / 1388 (12.03)
- Sore throat: 48 (73.85) / 148 (65.49) / 1185 (10.27)

**Discussion**

**Principal Findings**

The COVID-19 pandemic has triggered numerous research endeavors that have focused on procuring a better understanding of the disease caused by the novel SARS-CoV-2. Agile and dynamic projects led to contemporaneous approaches with similar and comparable study designs. Menni et al [11] report of real-time symptom tracking tool to predict COVID-19 infections. The approach is based on a smartphone app available in the United Kingdom and United States; 2,618,862 participants were included and analyzed in order to design a prediction model. Simultaneously, a total of 22,327 participants reported potential COVID-19 symptoms on a smartphone-based app in Germany. However, unlike the cohort discussed in this work, the British cohort did not represent the general population (eg, overrepresentation of female participants).

Menni et al [11] suggested that loss of smell and taste should be included in routine screening for COVID-19. We strongly agree with this opinion as our data also suggest a strong predictive value. Although chills and fever are found in COVID-19 patients with a higher probability, in a clinical setting a loss of smell and taste is unique and allows a better differentiation from other infectious diseases since many are accompanied by chills and fever. In the present situation, we suggest that loss of smell and taste, especially in combination with other symptoms, ought to be considered a red flag and should result in immediate testing for SARS-CoV-2 as well as isolation of the patient until the test result is obtained.

Furthermore, our work suggests that an increased awareness of gastrointestinal symptoms, namely nausea and vomiting, is needed as these have a stronger predictive value for a COVID-19 infection than symptoms such as sore throat or persistent cough, which are commonly considered as typical.

Apart from that, a significant association was seen between every symptom mentioned in this paper and a positive test result for SARS-CoV-2. This finding is explained by the preselection of symptoms that were reported to be associated with COVID-19 in prior publications.

Manual screening of the answers to the open question which asked for additional symptoms revealed an accumulation of the following symptoms: vertigo, painful ears or eyes, burning sensation of the tongue, and thoracic pain. A static analysis of
these reported symptoms is not yet possible due to insufficient data but corresponding questions have been added to the questionnaire in an updated version of the smartphone app.

Diabetes was identified as a major risk factor for a symptomatic course of COVID-19 infection. Other studies reported an increased risk, rapid progression, and a worse prognosis in patients with diabetes mellitus [12,13]. The mechanism remains unclear and requires further investigation.

Limitations
The limitations of this study are mainly due to the self-reporting nature of our methodology for data retrieval. The design does not allow for the verification of the reported symptoms or test results. Apart from that, the participants are not invited or preselected and may not represent the general population. The use of a smartphone device may have resulted in an underrepresentation of older adults. Another possible limitation is the small number of participants that had been tested for SARS-CoV-2 infection. A possible correlation between age, gender, and postal code (demographic information) and individual symptoms was not considered in the univariate analysis of symptoms.

Conclusions
Self-reported symptom tracking may help to identify novel symptoms of COVID-19 and estimate the predictive value of certain symptoms [14]. This may aid in the development of reliable screening tools. Clinical screening with a high pretest probability allows for the rapid identification of infections and serves as a cost-effective use of testing resources. Our data stress the necessity for an awareness of loss of smell and taste as cardinal symptoms.

Acknowledgments
The authors would like to express their sincere thanks to all the participants who voluntarily entered the study and shared information on their personal health and well-being. We thank the Ministerium fuer Wissenschaft, Forschung und Kunst, Baden-Wuerttemberg for an initial funding of the research platform, which was the foundation for the COVID-19 Symptom Tracker app. Furthermore, we would like to thank J Spieler, data protection officer at the University Medical Center Freiburg, for his support. The article processing fee was funded by the Baden-Wuerttemberg Ministry of Science, Research and Art and the University of Freiburg through the Open Access Publishing funding program in cooperation with a grant from Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte eV.

Authors’ Contributions
AB designed the app and database. MZ, JH, and MH developed the study questionnaires. MZ and NPS analyzed the data and plotted the results of the statistical analysis. MZ and JH wrote the manuscript. All authors revised the manuscript.

Conflicts of Interest
AB is the CEO of DESIGN-IT GmbH.

References
1. COVID-19 Coronavirus Pandemic. Worldometer. 2020. URL: https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas12 [accessed 2020-06-26]
2. Zheng Y, Ma Y, Zhang J, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020 May 5;17(5):259-260 [FREE Full text] [doi: 10.1038/s41569-020-0360-5] [Medline: 32139904]
3. Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol 2020 Jun 9;16(6):308-310 [FREE Full text] [doi: 10.1038/s41581-020-0284-7] [Medline: 32273593]
4. martinzens / covid-19-st. GitHub. 2020. URL: https://github.com/martinzens/covid-19-st [accessed 2020-08-26]
5. Statistisches Bundesamt. German Federal Office of Statistics. URL: https://www.destatis.de [accessed 2020-08-26]
6. COVID-19 in Deutschland. Robert Kock Institute. URL: https://www.rki.de/DE/Home/homepage_node.html [accessed 2020-08-26]
7. Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond) 2020 Mar 05;20(2):124–127 [FREE Full text] [doi: 10.7861/clinmed.2019-coron] [Medline: 3213972]
8. Gane S, Kelly C, Hopkins C. Isolated Sudden Onset Anosmia in COVID-19 Infection. A Novel Syndrome? Rhin 2020 Jun 01;58(3):299-301. [doi: 10.4193/rhin20.114]
9. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med 2020 May 4;35(5):1545-1549 [FREE Full text] [doi: 10.1007/s11606-020-05762-w] [Medline: 32133578]
10. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020 Apr 30;382(18):1708-1720 [FREE Full text] [doi: 10.1056/NEJMoa2002032] [Medline: 32109013]
11. Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med 2020 Jul 11;26(7):1037-1040 [FREE Full text] [doi: 10.1038/s41591-020-0916-2] [Medline: 32393804]
12. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev 2020 Mar 31:e3319 [FREE Full text] [doi: 10.1002/dmrr.3319] [Medline: 32233013]

13. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab 2020 May 01;318(5):E736-E741 [FREE Full text] [doi: 10.1152/ajpendo.00124.2020] [Medline: 32228322]

14. Rossman H, Keshet A, Shilo S, Gavrieli A, Bauman T, Cohen O, et al. A framework for identifying regional outbreak and spread of COVID-19 from one-minute population-wide surveys. Nat Med 2020 May;26(5):634-638 [FREE Full text] [doi: 10.1038/s41591-020-0857-9] [Medline: 32273611]

Abbreviations

OR: odds ratio
RT-PCR: reverse transcription-polymerase chain reaction